GET DAILY SIGNALSBrightSpring Health Services (BTSGU) Units Rise +13% on Strong Q3 Results
Key Takeaways
- BrightSpring Health Services' 6.75% tangible equity units (BTSGU) climbed roughly 13% over the past 30 days, rising from about $199 in early October to approximately $225.
- The move was driven by a strong third-quarter report released October 30, in which revenue rose 26% to $4.2 billion and adjusted EBITDA jumped 42% to $228 million.
- Management raised full-year 2026 guidance to $15.9–$16.125 billion in revenue and $850–$860 million in adjusted EBITDA.
- Specialty & Infusion revenue grew 34% and home health census rose roughly 58%, while the Inflation Reduction Act (IRA) weighed on the Home & Community Pharmacy line.
- Because the units are thinly traded, their price swings can be amplified relative to BrightSpring's common stock (BTSG), which rose roughly 12% on the same earnings news.
- Get more detail on BrightSpring's Price Targets, Earnings, and Forecast pages to review valuation and outlook data.
Company Overview and Market Position
BrightSpring Health Services, Inc. is a Louisville, Kentucky-based home and community healthcare services platform founded in 1974. The company operates through two segments: Pharmacy Solutions, which includes infusion, specialty, and home and community pharmacy services, and Provider Services, which spans home health, hospice, rehabilitation, personal care, and primary care. Serving complex senior and specialty populations across all 50 states with roughly 23,500 employees, BrightSpring is paid primarily by Medicare, Medicaid, and commercial payors. BTSGU is the ticker for the company's 6.75% tangible equity units, a separate security from the common shares traded under BTSG. Investors follow the company for its scale, integrated pharmacy-plus-care model, and consistent double-digit growth since its January 2024 IPO. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, the tangible equity units advanced approximately 13%, moving from roughly $199 in early October to about $225. The advance was concentrated around the late-October earnings release, when the units jumped by a double-digit percentage as BrightSpring's common stock rallied. For context, the units remain below their 52-week high of $255.51 set on June 17, 2026, and above their 52-week low of $105.89.
The quarterly picture is more mixed. After peaking in mid-June, the units pulled back for several months and traded near $184–$197 by mid-October before the earnings-driven rebound. Net over the trailing three months, the units are roughly flat to modestly higher, reflecting a sharp round trip rather than a straight-line advance. One thing that stands out here is the liquidity difference between the units and the common shares.
What Drove the Recent 30-Day Move
The dominant catalyst was BrightSpring's third-quarter 2026 earnings, reported on October 30. Revenue rose 26% year over year to $4.2 billion, adjusted EBITDA increased 42% to $228 million, and adjusted EPS reached $0.54, above analyst expectations. Management simultaneously raised full-year 2026 revenue guidance to $15.9–$16.125 billion and adjusted EBITDA guidance to $850–$860 million, signaling sustained momentum.
Segment results reinforced the story. Specialty & Infusion revenue grew 34% on 29% script growth, and home health census rose about 58%, helped by branches acquired from the Amedisys and LHC Group divestiture. Operating cash flow reached $204 million for the quarter, and leverage declined to 1.79 times. These positives outweighed a 6% decline in Home & Community Pharmacy revenue tied to IRA-related headwinds and the exit of uneconomic customers. The units' thin trading volume also amplified the upward move relative to the common stock.
Performance Over the Past Quarter
Over the past quarter, the units traced a volatile path. After reaching $255.51 in mid-June, the security entered a multi-month pullback, slipping toward the mid-$180s by mid-October as investors weighed elevated valuation and policy risk. The late-October earnings beat reversed that trend, restoring confidence in the company's growth trajectory and pushing the units back above $220. Analyst actions during the period, including maintained Buy, Outperform, and Overweight ratings from firms covering the common stock, provided a supportive backdrop. The overarching narrative has been one of strong operating fundamentals occasionally punctuated by liquidity-driven swings in the units themselves. I’m watching this closely for any signs of sustained momentum.
Key Drivers to Monitor Going Forward
Looking ahead, investors should monitor BrightSpring's fourth-quarter results and whether the company sustains its raised full-year trajectory. Key items include gross profit per script, Specialty & Infusion script growth, home health census, and the ongoing IRA impact on Home & Community Pharmacy, which management estimates at roughly $50 million in the fourth quarter. Management reiterated expectations for at least 15–20% organic adjusted EBITDA growth in 2027 off a larger base, and full 2027 guidance is expected with fourth-quarter results. Broader factors such as Medicare and Medicaid reimbursement policy, M&A activity, and valuation levels will also influence the units, which can be more volatile than the common stock given their limited liquidity. From what I see, reviewing forecasts on reliable platforms helps put these variables in perspective.
Exploring Tickeron’s Trending AI Robots
In my own research process, I often turn to Tickeron’s Trending AI Robots page to review a curated selection of AI-powered trading bots. It draws from a large universe of strategies but highlights only the top-performing and most relevant ones, covering different timeframes and approaches. This gives a practical starting point for evaluating systematic tools without sifting through everything manually.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
Aroon Indicator for BTSGU shows an upward move is likely
BTSGU's Aroon Indicator triggered a bullish signal on November 05, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 184 similar instances where the Aroon Indicator showed a similar pattern. In 163 of the 184 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
BTSGU moved above its 50-day moving average on October 05, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for BTSGU crossed bullishly above the 50-day moving average on October 13, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 4 of 6 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for BTSGU turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 27 similar instances when the indicator turned negative. In 10 of the 27 cases the stock turned lower in the days that followed. This puts the odds of success at 37%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 17 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (4.477). P/E Ratio (0.000) is within average values for comparable stocks, (13.414). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.016) settles around the average of (0.011) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (6.065).
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. BTSGU’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BTSGU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement